AI Article Synopsis
Article Abstract
Objective: Soft-tissue sarcomas are most frequently located deep within myofascial compartments. Superficial soft-tissue sarcomas (S-STS) are relatively less common and may be managed differently than deep sarcomas because generous resection margins are often possible without sacrificing critical structures. We sought to investigate the frequency and types of soft-tissue reconstructive procedures that are required following excision of S-STS.
Methods: We reviewed 457 consecutively treated patients with S-STS with a minimum 2-year follow-up from our prospectively maintained database between 1989 and 2009.
Results: Mean follow-up was 10.5 years (range, 2-23). Four hundred twenty-one tumors (91%) were excised with negative margins, 38 (8.3%) had microscopically positive margins, and three (0.7%) had grossly positive margins. One patient required an amputation. In 271 (58%) patients, the wounds were closed primarily. In comparison, 93 patients (20%) required a rotation flap, 70 (15%) required a split-thickness skin graft, and 23 (5%) underwent a free tissue transfer (ie, advanced reconstructive procedure). The overall complication rate was 12%, although 43% of patients undergoing free tissue transfer developed complications ( = 0.04). An unplanned excision before referral to our center was a risk factor for local recurrence ( = 0.03) when residual tumor was recovered in the reexcision specimen pathologically.
Conclusions: Although concern about the morbidity associated with a free tissue transfer (ie, advanced reconstructive procedure) may potentially limit the adequacy of resection in some patients with S-STS, the results of this study showed that the majority of patients had complete excisions with negative margins and primary closure. Obtaining a negative margin when excising a known or suspected S-STS rarely requires an advanced reconstructive procedure and almost never results in loss of limb.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732665 | PMC |
| http://dx.doi.org/10.1097/GOX.0000000000001553 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic Value of N1/N2 Neutrophils Heterogeneity and Tertiary Lymphoid Structure in Hepatocellular Carcinoma Patients.
Cancer Med
December 2024
Department of Gastroenterology, Peking University Third Hospital, Beijing, China.
Background: The tumor immune microenvironment, including neutrophils and tertiary lymphoid structures (TLSs), is pivotal for HCC prognosis assessment. Tumor-associated neutrophils exhibit plasticity, adopting either an antitumorigenic N1 (MPO+ CD206-) or a pro-tumorigenic N2 (MPO+ CD206+) phenotype. We explored the prognostic value of neutrophil plasticity and TLS maturity in HCC in both tumor and peritumoral tissues and addressed their interaction.
View Article and Find Full Text PDFAdagrasib in KRYSTAL-12 has Not Broken the KRAS G12C Enigma Code of the Unspoken 6-Month PFS Barrier in NSCLC.
Lung Cancer (Auckl)
December 2024
University of California Irvine School of Medicine, Department of Medicine, Orange, CA, 92868, USA.
Mutations in KRAS G12C are among the more common oncogenic driver mutations in non-small cell lung cancer (NSCLC). In December 2022, the US Food and Drug Administration (FDA) granted accelerated approval to adagrasib, a small molecule covalent inhibitor of KRAS G12C, for the treatment of patients with locally advanced or metastatic KRAS G12C mutant NSCLC who received at least one prior systemic therapy based on promising results from phase 1 and 2 trials wherein adagrasib demonstrated a median PFS of 6.5 months.
View Article and Find Full Text PDFOrthoplastic Approach to the Treatment and Reconstruction of a Neurotrophic Receptor Tyrosine Kinase Type 3 Soft Tissue Sarcoma Arising From the Occipitalis Muscle.
Cureus
November 2024
Medical Oncology, Parkview Health, Fort Wayne, USA.
We present a multidisciplinary approach to the treatment of a neurotrophic receptor tyrosine kinase type 3 (NTRK3) soft tissue sarcoma (STS), arising from the occipitalis muscle. NTRK3 is a mutation only recently described in STS using next-generation sequencing and is rarely implicated in STS.Currently, there is limited literature to guide care.
View Article and Find Full Text PDFLoss of SMARCA4 induces sarcomatogenesis through epithelial-mesenchymal transition in ovarian carcinosarcoma.
Cancer Sci
December 2024
Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Ovarian carcinosarcoma (OCS) is a rare and aggressive tumor, and the development of its sarcomatous component is believed to be due to epithelial-mesenchymal transition (EMT). The SWIch/sucrose nonfermentable chromatin remodeling factor (CRF) is closely related to EMT; however, the relationship between CRF and EMT in OCS remains unclear. In this study, we analyzed the protein expression of CRFs, including ARID1A and SMARCA4, and their downstream mRNA expression in 28 OCS cases, two fallopian tube CS cases, and one peritoneal CS case.
View Article and Find Full Text PDF[Impact of tumor size on actuarial survival of patients with primary breast sarcoma: a case-control study].
Khirurgiia (Mosk)
December 2024
School of Medicine, Antenor Orrego Private University, Trujillo, Peru.
Objective. T: O determine whether tumor size, categorized as >5 cm or ≤5 cm, influences overall survival in patients with primary breast sarcoma.
Material And Methods: The study population consisted of patients diagnosed with primary breast sarcoma between January 1, 2010, and December 31, 2020.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!